Comparative Pharmacology
Head-to-head clinical analysis: NILANDRON versus NILUTAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NILANDRON versus NILUTAMIDE.
NILANDRON vs NILUTAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of androgen binding to androgen receptors, reducing androgen-mediated growth of prostate cancer cells. Also inhibits testicular and adrenal androgen synthesis.
Nonsteroidal antiandrogen that competitively inhibits androgen binding to androgen receptors, blocking androgen action in target tissues.
300 mg orally three times a day.
300 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 7-8 hours; clinically relevant for twice-daily dosing.
The terminal elimination half-life is approximately 38–56 hours (mean ~49 hours), allowing once-daily dosing. Steady-state is achieved after about 7–10 days.
Clinical Note
moderateNilutamide + Digoxin
"Nilutamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNilutamide + Digitoxin
"Nilutamide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateNilutamide + Deslanoside
"Nilutamide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateNilutamide + Acetyldigitoxin
"Nilutamide may decrease the cardiotoxic activities of Acetyldigitoxin."
Renal: 55-60% as unchanged drug; fecal: 20-30% as metabolites; biliary: minor (<10%).
Nilutamide is extensively metabolized; less than 2% of the dose is excreted unchanged in urine. The majority of metabolites (approximately 70%) are excreted renally, with the remainder (about 30%) eliminated in feces via biliary excretion.
Category C
Category C
Antiandrogen
Antiandrogen